The clash between the FDA's legal lag and an overzealous industry could lead to patient harm and damage the agency's ability to oversee new technologies.
Read Full Article »The clash between the FDA's legal lag and an overzealous industry could lead to patient harm and damage the agency's ability to oversee new technologies.
Read Full Article »